Role of CX3CR1-expressing Cells in Hematologic Malignancy
Clinical Significance of CX3CR1 Adhesion Molecule-expressing Myeloid and Lymphoid Cells in Hematologic Malignancy
This study evaluates the clinical significance of CX3CR1-expressing myeloid and lymphoid cells in patients of hematologic malignancy.
Tumor cells either express membrane molecules or release tumor-derived soluble factors able to alter myelopoiesis and lymphopoiesis. Myeloid cells expressing CD11b play a critical role in sustaining cancer progression. Also, the fractalkine (CX3CL1; Fkn)/CX3CR1 axis plays an important function in the pathophysiology of various forms of cancers. Fkn is the only known ligand for CX3CR1, and it triggers recruitment of CX3CR1-positive cells through its unique receptor, CX3CR1. Therefore, the investigators focused the prognostic significance of CD11b+ myelo-monocytic cells expressing CX3CR1 and CD3+ lymphoid cells expressing CX3CR1 in the clinical outcomes of newly diagnosed Diffuse Large B-cell Lymphoma (DLBCL) and Multiple myeloma (MM).
研究概览
地位
详细说明
Bone marrow aspirates will be obtained from newly diagnosed MM and DLBCL patients at the time of diagnosis and relapse. Peripheral blood will be obtained at the time of diagnosis, finishing treatment, 3 months after treatment and relapse.
The investigators will analyze the cell fractions of CD11b+ CX3CR1+ cells and CD3+CX3CR1+ cells in blood samples by flowcytometry. The investigators will find out the relationship between the tested cells and clinical outcome in MM and DLBCL.
研究类型
注册 (预期的)
联系人和位置
学习联系方式
- 姓名:Jeong-A Kim, MD, Ph.D
- 电话号码:82-31-249-8456
- 邮箱:jakimapril@gmail.com
学习地点
-
-
Gyeonggi-do
-
Suwon-si、Gyeonggi-do、大韩民国、#16247
- 招聘中
- The Catholic University of Korea, St.Vincent's hospital
-
接触:
- Jeong-A Kim, MD, Ph.D
- 电话号码:82-31-249-8456
- 邮箱:jakimapril@gmail.com
-
首席研究员:
- Jeong-A Kim, MD, Ph.D
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- Subject newly diagnosed multiple myeloma.
- Subject newly diagnosed diffuse large B cell lymphoma.
Exclusion Criteria:
- History of other hematologic malignancy
- History of previous chemotherapy
学习计划
研究是如何设计的?
设计细节
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
---|---|
无进展生存期
大体时间:3年
|
3年
|
次要结果测量
结果测量 |
大体时间 |
---|---|
总生存期
大体时间:3年
|
3年
|
死亡
大体时间:3年
|
3年
|
合作者和调查者
调查人员
- 首席研究员:Jeong-A Kim, MD, Ph.D、Saint Vincent's Hospital, Korea
研究记录日期
研究主要日期
学习开始
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.